ALTEOGEN Inc. (KOSDAQ:196170)
433,500
+15,500 (3.71%)
Aug 29, 2025, 11:40 AM KST
ALTEOGEN Revenue
ALTEOGEN had revenue of 18.64B KRW in the quarter ending June 30, 2025, with 52.39% growth. This brings the company's revenue in the last twelve months to 158.06B, up 74.10% year-over-year. In the year 2024, ALTEOGEN had annual revenue of 102.85B with 6.56% growth.
Revenue (ttm)
158.06B
Revenue Growth
+74.10%
P/S Ratio
141.33
Revenue / Employee
1.02B
Employees
155
Market Cap
22.34T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
Dec 31, 2020 | 42.43B | 13.20B | 45.15% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
PharmaResearch | 392.31B |
Peptron | 4.30B |
LigaChem Biosciences | 146.42B |
ABL Bio | 94.93B |